Author: Newsdesk

SANTA ANA, Calif., June 17, 2026 (GLOBE NEWSWIRE) — TTM Technologies, Inc. (NASDAQ: TTMI) (“TTM”), a leading global manufacturer of technology products, including mission systems, radio frequency (“RF”) components, RF microwave/microelectronic assemblies, and technologically advanced interconnect products, including printed circuit boards (“PCB”s) and substrates, announced today the intent to acquire, subject to regulatory approvals, two well established companies in Europe: privately-held Swiss Technology Group AG (“STG”), headquartered in Zurich, Switzerland, and privately-held ILFA GmbH (“ILFA”), headquartered in Hannover, Germany, in separate transactions for all-cash consideration.

STG, through its underlying businesses, has a long history of interconnect solution leadership in Europe and was created through the merger of GS Swiss and the Hofstetter Group in 2023. The Company is a natural addition to TTM with its focus on miniaturized and small form-factor technology applications, primarily for the Medical end market but also with highly relevant technology for other markets of strategic importance such as Aerospace & Defense. STG produces rigid, rigid-flex, and flex printed circuit board (“PCB”) solutions as well as manufacturing and coating capabilities for miniaturized microcircuits. STG operates facilities in both Switzerland and Germany and boasts a global customer base that includes leading manufacturers in surgical robotics, hearing aids, medical imaging and implantable solutions.

ILFA has a 45-year legacy as a German provider of complex PCB solutions spanning Aerospace & Defense, Industrial, and Medical technology markets. Like STG, ILFA brings manufacturing of rigid, flexible, or rigid-flex PCBs, and also adds CAD services to enhance prototyping and production for various PCB designs. ILFA also possesses multiple strategically valuable certifications for electro-optical PCBs, processes for embedding components, and the integration of fluid channels.

“Consistent with our updated long-term strategy, these smaller but meaningful acquisitions establish our initial footprint in the important European market, adding healthy “long-cycle” businesses with strategic technology capabilities to the TTM portfolio, reinforcing our “up the chain” value-add technology approach,” said Edwin Roks, President and Chief Executive Officer of TTM Technologies. “The acquisitions of Swiss Technology Group AG and ILFA demonstrate TTM’s strategic commitment to diversification through both product and geographic means, expand our technology solution capabilities and also build on our legacy applications.” Dr. Roks added.

Citi is serving as the exclusive financial advisor to TTM for the potential acquisition of STG and Piper Sandler & Co. is serving as financial advisor to STG. The combined acquisitions are expected to be immediately, albeit modestly, accretive when completed following regulatory approvals and excluding purchase accounting adjustments and similar factors. It is expected that these transactions will close in the third quarter of 2026. TTM expects to provide additional insight for investors during its formal second quarter earnings call that is currently projected for early August.

About TTM

TTM Technologies, Inc. is a leading global manufacturer of technology products, including mission systems, radio frequency (“RF”) components, RF microwave/microelectronic assemblies, and technologically advanced interconnect products, including PCBs and substrates. TTM stands for time-to-market, representing how TTM’s time-critical, one-stop design, engineering and manufacturing services enable customers to reduce the time required to develop new products and bring them to market. Additional information can be found at www.ttm.com.

About Swiss Technology Group AG

STG Swiss Technology Group AG is a platform of two industry leaders: GS Swiss and the Hofstetter Group, combining their strengths to deliver vertically integrated, cutting-edge solutions for the most demanding medical applications. GS Swiss specializes in highly miniaturized microcircuits designed for the medical technology sector including implantable neurostimulators, leadless pacemakers, cochlear implants, and other high-performance medical devices. The Hofstetter Group is Europe’s foremost full-service provider of microcircuit coating solutions, offering an extensive portfolio of advanced processes for assembly, connection technology, as well as final surface treatment. Its innovative capabilities cater primarily to the medical technology industry while also addressing dynamic growth sectors across Industrial markets. Additional information can be found at https://www.swiss-technology-group.com/.

About ILFA GmbH

ILFA is a German PCB manufacturer headquartered in Hannover. The owner-managed company with around 190 employees has been producing innovative ultra-fine and micro-fine conductor solutions in the high-tech segment for 45 years. With its location in Kirchheimbolanden near Frankfurt a.M.both national and international customers are served. ILFA’s range of services includes CAD services for the creation of the design of prototypes, small series through to the further development of large series. Both single and double-sided PCBs are manufactured, as well as multilayers with more than 30 layers. Depending on the application, the board is designed as a classic rigid, flexible or rigid-flexible PCB. This also applies to the high layer area. ILFA has numerous certifications, realizes complex hybrid structures and has the manufacturing competence of electro-optical PCBs, the embedding of components or the integration of fluid channels. Additional information can be found at https://ilfa.de/

Safe Harbor Forward-Looking Statements

This release contains forward-looking statements that relate to future events or performance. TTM cautions you that such statements are simply predictions and actual events or results may differ materially. These statements reflect TTM’s current expectations, and TTM does not undertake to update or revise these forward-looking statements, even if experience or future changes make it clear that any projected results expressed or implied in this or other TTM statements will not be realized. Further, these statements involve risks and uncertainties, many of which are beyond TTM’s control, which could cause actual results to differ materially from the forward-looking statements. These risks and uncertainties include, but are not limited to, general market and economic conditions, including interest rates, currency exchange rates, and consumer spending, demand for TTM’s products, market pressures on prices of TTM’s products, warranty claims, changes in product mix, contemplated significant capital expenditures and related financing requirements, TTM’s dependence upon a small number of customers, and other factors set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of TTM’s public reports filed with the SEC.

Contact:

Sean K.F. Hannan,
Vice President, Investor Relations
[email protected]
+1 339 466 7737

ATLANTA, June 17, 2026 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Gildan Activewear Inc. (“Gildan” or the “Company”) (NYSE: GIL) complied with federal securities laws. On June 16, 2026, Jehoshaphat Research published a report alleging that it believes Gildan “has been inflating its revenues through channel stuffing for years but is finally running out of room to do so, and this will expose the weaker revenue and earnings profile of the business.” The price of the Company’s stock dropped following this report.

If you purchased Gildan stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at [email protected] or Joshua Karr, Esq. at [email protected], call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/gildan-activewear/ to discuss your legal rights.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  

CONTACT:
Corey Holzer, Esq. 
(888) 508-6832 (toll-free)
[email protected]

PRINCETON, N.J., June 17, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced Magnolia Square at Princeton, an intimate community of 24 luxury townhomes in Princeton, New Jersey, is now open for sale. The community’s Sales Center is located within Toll Brothers’ nearby Regency at West Windsor community at 2 Meade Drive in West Windsor.

Magnolia Square at Princeton features modern, open-concept home designs up to 2,500 square feet. Each home includes 3 bedrooms, 2.5 bathrooms, loft spaces leading to private rooftop terraces, and two-car garages. Homes are priced from $1.47 million.

Situated in a highly desirable location, Magnolia Square at Princeton provides walkable access to shopping and dining at the Princeton Shopping Center and nearby Grover Park. Home shoppers will also enjoy easy access to commuter hubs such as Princeton Station and Princeton Junction Station, offering convenient travel to New York, Philadelphia, and beyond. Additionally, the community is located within the sought-after Princeton Public Schools district, making it an attractive option for families.

“Magnolia Square at Princeton is an exclusive community offering a rare combination of luxury living and convenience in one of the most desirable locations in New Jersey,” said Jill Sarcia, Division President of Toll Brothers in New Jersey. “We are thrilled to bring this exceptional new home opportunity to the Princeton area.”

Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows home shoppers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants.

Magnolia Square at Princeton offers low-maintenance living with lawn care and snow removal included, as well as advanced geothermal heating and cooling systems for year-round comfort and energy efficiency.

For more information about Magnolia Square at Princeton, call 844-834-5263 or visit TollBrothers.com/NJ.

About Toll Brothers

Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses.

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies^®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | [email protected]

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/2ff8b10c-54d9-4bc7-ab16-6e72ec95f386

https://www.globenewswire.com/NewsRoom/AttachmentNg/f42822a1-f3fe-4503-a56e-7362047ddd53 

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)

TORONTO, June 17, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today the results of its Annual Meeting of Shareholders held June 17, 2026 (the “Meeting”).

Satellos is pleased to announce that all the nominees listed in the management information circular dated May 14, 2026 (the “Circular”) were elected as directors. Shareholders present at the Meeting or represented by proxy totaled 55.3% of the issued and outstanding common shares of the Company.

The results of the vote are detailed below:

Director	Votes For		% For		Votes Against		% Against
Frank Gleeson	9,473,905		99.94		5,348		0.06
Franklin M. Berger	9,478,576		99.99		677		0.01
Brian Bloom	9,476,755		99.97		2,498		0.03
Stephanie Brown	8,741,404		92.22		737,849		7.78
Selwyn Ho	9,473,538		99.94		5,715		0.06
Iris Loew-Friedrich	7,939,800		83.76		1,539,453		16.24
Geoff Mackay	9,449,959		99.69		29,294		0.31
Adam Mostafa	9,450,311		99.69		28,942		0.31
Mark Nawacki	9,477,041		99.98		2,212		0.02

Satellos shareholders also voted in favor of the re-appointment of PricewaterhouseCoopers LLP as auditors of the Company.

Please refer to Circular available on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov) for more details on the matters covered at the Meeting. Final voting results on all matters voted on at the Meeting will also be filed on SEDAR+ and EDGAR.

ABOUT SATELLOS BIOSCIENCE INC.

Satellos is a clinical-stage drug development company advancing SAT-3247, a first-of-its-kind, orally administered small molecule therapy designed to reset the body’s natural muscle repair and regeneration process in degenerative muscle diseases. SAT-3247 is being evaluated as a potential disease-modifying treatment, initially for DMD, in two Phase II clinical trials: BASECAMP in pediatrics and TRAILHEAD in adults. SAT-3247 targets AAK1, a protein that is a key regulator of the body’s natural muscle repair and regeneration biology, which Satellos discovered is disrupted in DMD and other degenerative conditions. By inhibiting AAK1, SAT-3247 is designed to re-establish a critical biochemical signal needed to guide this process, in a dystrophin-independent manner. This mechanistic feature offers SAT-3247 the potential for broad applicability as either a stand-alone treatment to potentially enhance muscle and function, or as adjunctive therapy alongside other approaches. Satellos has identified additional degenerative muscle diseases where enhancing muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com.

NOTICE ON FORWARD-LOOKING STATEMENTS

This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the potential of our approach in other degenerative muscle diseases and our plans to pursue those opportunities. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often, but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective” , “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. These statements are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks and uncertainties described in more detail in the “Risk Factors” section of Satellos’ Annual Information Form dated March 27, 2026 (which is located on Satellos’ profile at www.sedarplus.ca) and in Satellos’ public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise

CONTACTS

Investors: Dan Ferry, LifeSci Advisors, [email protected]
Media: Emily Williams, Senior Director of Communications, [email protected]

BROOKFIELD, NEWS, June 17, 2026 (GLOBE NEWSWIRE) — Brookfield Renewable Corporation (the “Corporation”) (TSX, NYSE: BEPC) today announced that all eight nominees proposed for election to the board of directors of the Corporation by holders of class A exchangeable subordinate voting shares (“Exchangeable Shares”) and holders of class B multiple voting shares (“Class B Shares”) were elected at the Corporation’s annual meeting of shareholders held on June 17, 2026 in a virtual meeting format and that Ernst & Young LLP have been re-appointed as the corporation’s external auditor. Detailed results of the vote for the election of directors are set out below.

In accordance with the Corporation’s articles, each Exchangeable Share was entitled to one vote per share, representing a 25% voting interest in the Corporation in the aggregate, and the Class B Shares were entitled to a total of 442,985,718 votes in the aggregate, representing a 75% voting interest in the Corporation.

The following is a summary of the votes cast by holders of Exchangeable Shares and Class B Shares, voting together as a single class, in regard to the election of the eight directors:

Director Nominee	Votes For	%	Votes Withheld	%
Jeffrey Blidner	497,570,427	91.47%	46,402,256	8.53%
Sarah Deasley	543,218,258	99.86%	754,422	0.14%
Nancy Dorn	541,213,223	99.49%	2,759,458	0.51%
Eleazar de Carvalho Filho	543,031,902	99.83%	940,782	0.17%
Randy MacEwen	543,104,031	99.84%	868,651	0.16%
Lou Maroun	533,966,172	98.16%	10,006,511	1.84%
Stephen Westwell	541,209,843	99.49%	2,762,840	0.51%
Patricia Zuccotti	542,966,251	99.81%	1,006,431	0.19%

A summary of all votes cast by holders of the Exchangeable Shares and Class B Shares represented at the Corporation’s annual meeting of shareholders is available on SEDAR+ at www.sedarplus.ca.

Brookfield Renewable

Brookfield Renewable operates one of the world’s largest publicly traded platforms for renewable power and sustainable solutions. Our renewable power portfolio consists of hydroelectric, wind, utility-scale solar, distributed solar, and storage facilities and our sustainable solutions assets include our investment in a leading global nuclear services business and a portfolio of investments in carbon capture and storage capacity, agricultural renewable natural gas, materials recycling and eFuels manufacturing capacity, among others.

Investors can access the portfolio either through Brookfield Renewable Partners L.P. (NYSE: BEP; TSX: BEP.UN), a Bermuda-based limited partnership, or Brookfield Renewable Corporation (NYSE, TSX: BEPC), a Canadian corporation.

Brookfield Renewable is the flagship listed energy company of Brookfield Asset Management, a leading global alternative asset manager headquartered in New York, with over $1 trillion of assets under management.

Contact information:
Media:	Investors:
Simon Maine	Alex Jackson
+44 7398 909 278	+1 (416) 484-8525
[email protected]	[email protected]

EDMONTON, Alberta and NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) — TSX, NYSE:STN

Stantec, a global leader in sustainable design and engineering, announces today that Gord Johnston will retire as president and chief executive officer, effective October 1. Mr. Johnston will remain on the Board, taking on the role of vice chair. Susan Reisbord, currently chief operating officer of the North America business, has been appointed as the next president and chief executive officer.

“Susan is a proven leader with a strong track record of delivering results,” said Doug Ammerman, chair of Stantec’s Board of Directors. “Under Susan’s leadership, Stantec is well positioned to deliver on its commitments today, while advancing into its next chapter of growth, including the development and execution of the Company’s next Strategic Plan.”

“Susan is the right leader for Stantec’s next chapter,” said Mr. Johnston. “She understands our business, our strategy, and our culture, and will continue to drive operational excellence and growth across the company. I have full confidence in her and in the Company’s future.”

Deep Commitment to Continuity

This transition is the result of a long-standing, Board-led succession plan. Stantec’s client relationships, project delivery, and operational focus remain unchanged, reflecting the strength and consistency of its leadership platform.

Ms. Reisbord brings more than 30 years of experience in the industry, joining Stantec in 2021 with the acquisition of Cardno, where she was the CEO. Ms. Reisbord became the business operating unit leader for Stantec’s Environmental Services business line, before being promoted in 2025 to chief operating officer for North America, the company’s largest geographic operating unit.

“As I step into the role of CEO, I’m excited to do so from a position of strength and stability—which is a direct reflection of the quality of our people,” Ms. Reisbord said. “Stantec does astounding work that matters deeply to the clients and communities we serve. I’m proud to take this great company forward, and I thank Gord for the foundation he’s laid before me.”

A Strong Legacy, a Clear Path Forward

During his eight-and-a-half years as CEO, Mr. Johnston led Stantec through a period of significant transformation—strengthening its global platform, sharpening its strategic focus, and reinforcing a culture grounded in collaboration, technical excellence, and purpose. Under his leadership, Stantec advanced its position as a truly global, innovative, and resilient professional services firm, navigating industry cycles with discipline while continuing to invest in people, capabilities, and long-term growth.

“On behalf of the Board, I want to thank Gord for his outstanding leadership,” said Mr. Ammerman. “Over his tenure as CEO, he expanded our global footprint, refined our strategy, and built a deep, capable leadership team that positions the company well for the future.”

“As I step away from the role of president and CEO, I do so with great pride and gratitude—pride in our people and gratitude for all we’ve been able to accomplish together,” said Mr. Johnston. “Stantec is a strong company with a bright future. I have tremendous confidence in where it is headed under Susan’s leadership, and I look forward to continuing to support the Company’s success as vice chair of the Board.”

About Stantec

Stantec empowers clients, people, and communities to rise to the world’s greatest challenges at a time when the world faces more unprecedented concerns than ever before.   
​
We are a global leader in sustainable architecture, engineering, and environmental consulting. ​Our professionals deliver the expertise, technology, and innovation communities need to manage aging infrastructure, demographic and population changes, the energy transition, and more. ​

Today’s communities transcend geographic borders. At Stantec, community means everyone with an interest in the work that we do—from our project teams and industry colleagues to our clients and the people our work impacts. The diverse perspectives of our partners and interested parties drive us to think beyond what’s previously been done on critical issues like climate change, digital transformation, and future-proofing our cities and infrastructure.  ​

We are designers, engineers, scientists, project managers, and strategic advisors. We innovate at the intersection of community, creativity, and client relationships to advance communities everywhere, so that together we can redefine what’s possible.​

Stantec trades on the TSX and the NYSE under the symbol STN. Visit us at stantec.com or find us on social media.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements regarding the executive succession plan described above. By their nature, forward-looking statements are based on assumptions and subject to risks and uncertainties. There is a risk that the executive appointments described above may be accelerated, delayed, suspended or terminated. This could cause future results to differ materially from the forward-looking statements made in this news release. Except as may be required by law, Stantec undertakes no obligation to publicly update or revise any forward-looking statements. Forward-looking statements are provided herein for the purpose of giving information about the succession plan referred to above and its expected impact.

Readers are cautioned that such information may not be appropriate for other purposes.

Media Contact Danny Craig Director, Public Relations Ph: (949) 632-6319 [email protected]

Investor Contact Jess Nieukerk Stantec Investor Relations Ph: (403) 569-5389 [email protected]